ArticleFrontiers in immunology2017
Minimum Information about T Regulatory Cells: A Step toward Reproducibility and Standardization.
Abstract read
In one paragraph
Article in Frontiers in immunology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Dawn of Monitoring Regulatory T Cells in (Pre-)clinical Studies: Their Relevance Is Slowly Recognised.Frontiers in medicine · 2020Pooled it
- Safety and efficacy of the therapy with CD4 + CD25highCD127-T regulatory cells: When paediatric patient becomes adult.Diabetes, obesity & metabolism · 2026Article
- Delineating phenotypic heterogeneity in human regulatory T cells across developmental stages and therapeutic sources.Frontiers in immunology · 2026Article
- Automated GMP-compatible production of universal CAR Tregs for organ-targeted tolerance induction.Journal of translational medicine · 2025Article
- Advances in the treatment of systemic lupus erythematosus.Nature reviews. Drug discovery · 2025Review
- Regulatory T lymphocytes as a treatment method for rheumatoid arthritis - Superiority of allogeneic to autologous cells.Heliyon · 2024Review
- Defining Human Regulatory T Cells beyond FOXP3: The Need to Combine Phenotype with Function.Cells · 2024Review
- Clinical Manufacturing of Regulatory T Cell Products For Adoptive Cell Therapy and Strategies to Improve Therapeutic Efficacy.Organogenesis · 2023Review
- Tolerogenic dendritic cell reporting: Has a minimum information model made a difference?PeerJ · 2023Article
- Mesenchymal stem cells transfer mitochondria to allogeneic Tregs in an HLA-dependent manner improving their immunosuppressive activity.Nature communications · 2022Article
- Interleukin-2-inducible T-cell kinase (Itk) signaling regulates potent noncanonical regulatory T cells.Clinical and translational medicine · 2021Article
- Interleukin-2 and regulatory T cells in rheumatic diseases.Nature reviews. Rheumatology · 2021Review
- Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition).European journal of immunology · 2021Review
- A digital health platform for assisting the diagnosis and monitoring of COVID-19 progression: An adjuvant approach for augmenting the antiviral response and mitigating the immune-mediated target organ damage.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2021Article
- Therapeutically expanded human regulatory T-cells are super-suppressive due to HIF1A induced expression of CD73.Communications biology · 2021Article
- Advances in Liver Transplantation: where are we in the pursuit of transplantation tolerance?European journal of immunology · 2021Review
- Fortified Tregs to fight atherosclerosis.Cardiovascular research · 2021Article
- Paving the way towards an effective treatment for multiple sclerosis: advances in cell therapy.Cellular & molecular immunology · 2021Review
- First-in-human phase 1 trial of induced regulatory T cells for graft-versus-host disease prophylaxis in HLA-matched siblings.Blood advances · 2021Article
- Strong Expansion of Human Regulatory T Cells for Adoptive Cell Therapy Results in Epigenetic Changes Which May Impact Their Survival and Function.Frontiers in cell and developmental biology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
61 authors.
Anke FuchsGMP facility, DFG-Center for Regenerative Therapies Dresden (CRTD), Center for Molecular and Cellular Bioengineering (CMCB), and Department of Internal Medicine I, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
Mateusz GliwińskiDepartment of Clinical Immunology and Transplantology, Medical University of Gdańsk, Gdańsk, Poland.
Nathali GragedaMRC Centre for Transplantation, King's College London, Guy's Hospital, London, United Kingdom.
Rachel SpieringInstitute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom.
Abul K AbbasDepartment of Pathology, University of California, San Francisco, San Francisco, CA, United States.
Silke AppelBroegelmann Research Laboratory, Department of Clinical Science, University of Bergen, Bergen, Norway.
Rosa BacchettaPediatric Stem Cell Transplantation and Regenerative Medicine, Department of Pediatrics, Stanford School of Medicine, Stanford, CA, United States.
Manuela BattagliaDiabetes Research Institute, IRCCS San Raffaele Scientific Institute, and TrialNet Clinical Center, San Raffaele Hospital, Milan, Italy.
David BerglundDepartment of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.
Bruce BlazarDepartment of Pediatrics, Division of Blood and Marrow Transplantation, University of Minnesota, Minnesota, MN, United States.
Jeffrey A BluestoneHormone Research Institute, University of California, San Francisco, San Francisco, CA, United States.
Martin BornhäuserGMP facility, DFG-Center for Regenerative Therapies Dresden (CRTD), Center for Molecular and Cellular Bioengineering (CMCB), and Department of Internal Medicine I, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
Anja Ten BrinkeDepartment of Immunopathology, Sanquin Research and Landsteiner Laboratory, University of Amsterdam, Academic Medical Center, Amsterdam, Netherlands.
Todd M BruskoDepartment of Pathology, Immunology, and Laboratory Medicine, University of Florida Diabetes Institute, College of Medicine, Gainesville, FL, United States.
Nathalie CoolsLaboratory of Experimental Hematology, Vaccine & Infectious Disease Institute, Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp University Hospital (UZA), Edegem, Belgium.
Maria Cristina CuturiCentre de Recherche en Transplantation et Immunologie UMR1064, INSERM, Université de Nantes, Nantes, France.
Edward GeisslerDivision of Experimental Surgery, Department of Surgery, University Hospital Regensburg, Regensburg, Germany.
Nick GiannoukakisAllegheny Health Network, Institute of Cellular Therapeutics, Carnegie Mellon University, Pittsburgh, PA, United States.
Karolina GołabTransplant Institute, Department of Surgery, The University of Chicago, Chicago, IL, United States.
David A HaflerDepartments of Neurology and Immunobiology, Yale School of Medicine, New Haven, CT, United States.
S Marieke van HamDepartment of Immunopathology, Sanquin Research and Landsteiner Laboratory, University of Amsterdam, Academic Medical Center, Amsterdam, Netherlands.
Joanna HesterNuffield Department of Surgical Sciences, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom.
Keli HippenDepartment of Pediatrics, Division of Blood and Marrow Transplantation, University of Minnesota, Minnesota, MN, United States.
Mauro Di IanniDepartment of Medicine and Aging Sciences, University of Chieti-Pescara, Chieti, Italy.
Natasa IlicDepartment for Immunology and Immunoparasitology, National Reference Laboratory for Trichinellosis, Institute for the Application of Nuclear Energy, University of Belgrade, Belgrade, Serbia.
John IsaacsInstitute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom.
Fadi IssaNuffield Department of Surgical Sciences, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom.
Dorota Iwaszkiewicz-GrześDepartment of Clinical Immunology and Transplantology, Medical University of Gdańsk, Gdańsk, Poland.
Elmar JaeckelDepartment of Gastroenterology, Hepatology, Endocrinology, Diabetology, Transplantationsforschungszentrum, Medical School of Hannover (MHH), Hannover, Germany.
Irma JoostenLaboratory of Medical Immunology, Department of Laboratory Medicine, Radboudumc, Nijmegen, Netherlands.
David KlatzmannImmunology-Immunopathology-Immunotherapy (i3), UPMC Univ Paris 06, UMRS 959, Sorbonne Université, and Biotherapy (CIC-BTi) and Inflammation-Immunopathology-Biotherapy Department, AP-HP, Hôpital Pitié-Salpêtrière, Paris, France.
Hans KoenenLaboratory of Medical Immunology, Department of Laboratory Medicine, Radboudumc, Nijmegen, Netherlands.
Cees van KootenDepartment of Nephrology, Leiden University Medical Center, Leiden, Netherlands.
Olle KorsgrenDepartment of Immunology, Genetics and Pathology, Rudbeck Laboratory, Uppsala University Hospital, Uppsala, Sweden.
Karsten KretschmerMolecular and Cellular Immunology/Immune Regulation, DFG-Center for Regenerative Therapies Dresden (CRTD), Center for Molecular and Cellular Bioengineering (CMCB), Technische Universität Dresden, and Paul Langerhans Institute Dresden (PLID) of the Helmholtz Zentrum München at the University Hospital and Medical Faculty Carl Gustav Carus of TU Dresden, Dresden, Germany.
Megan LevingsDepartment of Surgery, Faculty of Medicine, The University of British Columbia, BC Children's Hospital Research Institute, Vancouver, BC, Canada.
Natalia Maria Marek-TrzonkowskaLaboratory of Immunoregulation and Cellular Therapies, Department of Family Medicine, Medical University of Gdańsk, Gdańsk, Poland.
Marc Martinez-LlordellaMedical Research Council Centre for Transplantation, Institute of Liver Studies, King's College London, London, United Kingdom.
Djordje MiljkovicDepartment of Immunology, IBISS, University of Belgrade, Belgrade, Serbia.
Kingston H G MillsImmune Regulation Research Group, School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland.
Joana P MirandaFaculty of Pharmacy, Research Institute for Medicines (iMed.ULisboa), Universidade de Lisboa, Lisbon, Portugal.
Ciriaco A PiccirilloDepartments of Microbiology & Immunology and Medicine, Faculty of Medicine, McGill University, Program in Infectious Disease and Immunity in Global Health, Centre of Excellence in Translational Immunology (CETI), Research Institute of McGill University Health Centre, Montréal, QC, Canada.
Amy L PutnamHormone Research Institute, University of California, San Francisco, San Francisco, CA, United States.
Thomas RitterCollege of Medicine, Nursing and Health Sciences, Regenerative Medicine Institute (REMEDI), Biomedical Sciences, National University of Ireland, Galway, Ireland.
Maria Grazia RoncaroloDivision of Stem Cell Transplantation and Regenerative Medicine, Department of Pediatrics, ISCBRM, Stanford School of Medicine, Stanford, CA, United States.
Shimon SakaguchiWPI Immunology Frontier Research Center, Osaka University, Osaka, Japan.
Silvia Sánchez-RamónDepartment of Clinical Immunology, Hospital Clínico San Carlos, Universidad Complutense of Madrid, Madrid, Spain.
Birgit SawitzkiInstitute for Medical Immunology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin, Germany.
Ljiljana Sofronic-MilosavljevicDepartment for Immunology and Immunoparasitology, National Reference Laboratory for Trichinellosis, Institute for the Application of Nuclear Energy, University of Belgrade, Belgrade, Serbia.
Megan SykesColumbia Center for Translational Immunology, Columbia University College of Physicians and Surgeons, Bone Marrow Transplantation Research, Division of Hematology/Oncology, Columbia University Medical Center, Columbia University, New York, NY, United States.
Qizhi TangDepartment of Surgery, University of California, San Francisco, San Francisco, CA, United States.
Marta Vives-PiImmunology of Diabetes Unit, Germans Trias i Pujol Research Institute (IGTP), Barcelona, Spain.
Herman WaldmannSir William Dunn School of Pathology, University of Oxford, Oxford, United Kingdom.
Piotr WitkowskiTransplant Institute, Department of Surgery, The University of Chicago, Chicago, IL, United States.
Kathryn J WoodNuffield Department of Surgical Sciences, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom.
Silvia GregoriMechanisms of Peripheral Tolerance Group, San Raffaele Telethon Institute for Gene Therapy (SR-TIGET), San Raffaele Scientific Institute IRCCS, Milan, Italy.
Catharien M U HilkensInstitute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom.
Giovanna LombardiMRC Centre for Transplantation, King's College London, Guy's Hospital, London, United Kingdom.
Phillip LordSchool of Computing, Newcastle University, Newcastle upon Tyne, United Kingdom.
Eva M Martinez-CaceresImmunology Division, Germans Trias i Pujol University Hospital - Can Ruti, Department Cellular Biology, Physiology, Immunology, Universitat Autònoma Barcelona, Badalona, Spain.
Piotr TrzonkowskiDepartment of Clinical Immunology and Transplantology, Medical University of Gdańsk, Gdańsk, Poland.
Funding
Project 3P01AI042288 · NIAID · UNIVERSITY OF FLORIDA · PI MARK A. ATKINSON · 1997 to 2026
$32.9MEnhancing Treg Therapeutic Efficacy in GVHDR01HL118979 · NHLBI · UNIVERSITY OF MINNESOTA · PI BLAZAR, BRUCE R, HIPPEN, KELI L · 2014 to 2025
$6.7MT-CELL TARGETING FOR GVHDR01HL056067 · NHLBI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI BLAZAR, BRUCE R · 1995 to 2022
$5.4MIn Vivo Prevention of Murine GVHDR37AI034495 · NIAID · UNIVERSITY OF MINNESOTA · PI Bruce R Blazar · 2017 to 2026
$5.4MThe CD226 costimulatory axis in type 1 diabetesR01DK106191 · NIDDK · UNIVERSITY OF FLORIDA · PI Todd Michael Brusko · 2016 to 2026
$4.4MBritish Heart Foundation RG/13/12/30395Medical Research Council G0800842Medical Research Council G1001518Medical Research Council MR/K025538/1Medical Research Council MR/N027930/1NHLBI NIH HHS R01 HL056067NHLBI NIH HHS R01 HL118979NIAID NIH HHS P01 AI042288NIAID NIH HHS R37 AI034495NIDDK NIH HHS R01 DK106191Versus Arthritis 18155
Abstract
Cellular therapies with CD4+ T regulatory cells (Tregs) hold promise of efficacious treatment for the variety of autoimmune and allergic diseases as well as posttransplant complications. Nevertheless, current manufacturing of Tregs as a cellular medicinal product varies between different laboratories, which in turn hampers precise comparisons of the results between the studies performed. While the number of clinical trials testing Tregs is already substantial, it seems to be crucial to provide some standardized characteristics of Treg products in order to minimize the problem. We have previously developed reporting guidelines called minimum information about tolerogenic antigen-presenting cells, which allows the comparison between different preparations of tolerance-inducing antigen-presenting cells. Having this experience, here we describe another minimum information about Tregs (MITREG). It is important to note that MITREG does not dictate how investigators should generate or characterize Tregs, but it does require investigators to report their Treg data in a consistent and transparent manner. We hope this will, therefore, be a useful tool facilitating standardized reporting on the manufacturing of Tregs, either for research purposes or for clinical application. This way MITREG might also be an important step toward more standardized and reproducible testing of the Tregs preparations in clinical applications.
Indexed as
cell therapygood manufacturing practiceimmune toleranceimmunotherapyminimum information modelT regulatory cells
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.